SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Durata Therapeutics, Inc. in Connection with the Sale of t...
11 Outubro 2014 - 8:05AM
Business Wire
Law office of Brodsky & Smith, LLC announces that it is
investigating potential claims against the Board of Directors of
Durata Therapeutics, Inc. (“Durata” or the “Company”) (Nasdaq:
DRTX) relating to the proposed acquisition by Actavis plc.
Click here to learn more about the investigation
http://brodsky-smith.com/836-drtx-durata-therapeutics-inc.html, or
call: 877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, Durata shareholders will
receive only $23.00 in cash for each share of Durata common stock
they own. In addition, stockholders of Durata will receive one
Contingent Value Right (CVR) which will entitled the holder to
receive an additional cash payment of up to $5.00 per share if
certain milestones are reached. However, there is no guarantee that
these milestones will ever be reached.
The investigation concerns possible breaches of fiduciary duty
and other violations of state law by the Board of Directors of
Durata for not acting in the Company’s shareholders best interests
in connection with the sale process. The transaction may undervalue
Durata as the Company recently announced a summary of presentation
data from its recently launched product DALVANCE ™ (dalbavancin).
Among the positive findings was data supporting further study in
Patients with osteomyelitis and prosthetic joint infections. A
separate analysis was also positive for patients with ABASSSI that
were treated with dalbavancin.
If you own shares of Durata common stock and wish to discuss the
legal ramifications of the investigation, or have any questions,
you may e-mail or call the law office of Brodsky & Smith, LLC
who will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L. Brodsky, Esquire or Evan J.
Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com, by visiting
http://brodsky-smith.com/836-drtx-durata-therapeutics-inc.html, or
calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive
expertise representing shareholders throughout the nation in
securities and case action lawsuits. The attorneys at Brodsky &
Smith have been appointed by numerous courts throughout the country
to serve as lead counsel in class actions and successfully
recovered millions of dollars for our clients and shareholders.
Attorney advertising. Prior results do not guarantee a similar
outcome.
Brodsky & Smith, LLCJason L. Brodsky, EsquireEvan J. Smith,
Esquire877-LEGAL-90investorrelations@brodsky-smith.comhttp://brodsky-smith.com/836-drtx-durata-therapeutics-inc.html
(MM) (NASDAQ:DRTX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
(MM) (NASDAQ:DRTX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024